2021
DOI: 10.18632/aging.203339
|View full text |Cite
|
Sign up to set email alerts
|

Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model

Abstract: Chronic intermittent hypoxia (CIH), a hallmark of obstructive sleep apnea (OSA), is associated with various cardiovascular diseases. In the present study, we assessed the effect of the lipid reducing agent atorvastatin on CIH-induced myocardial oxidative stress and apoptosis in a mouse OSA model. Forty-eight C57BL/6J mice were evenly divided among normoxia + vehicle, normoxia + atorvastatin, CIH + vehicle, and CIH + atorvastatin groups. CIH consisted of a hypoxia-reoxygenation cycle in which oxygen concentrati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 24 publications
0
1
0
Order By: Relevance
“…Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are a class of cholesterol-lowering medications that also possess cardiovascular protective effects [93]. Atorvastatin, which shows efficacy in attenuating chronic IH-induced myocardial and neural inflammation via suppressing TLR4/MyD88/NF-κB signaling pathways [33,40,94], also suppresses NLRP3 inflammasome activation [95], although this has not been tested in IH models. A recent clinical trial indicates promising protective effects of atorvastatin against cardiovascular risks in OSA patients [96].…”
Section: Mirna/nlrp3 Signalingmentioning
confidence: 99%
“…Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are a class of cholesterol-lowering medications that also possess cardiovascular protective effects [93]. Atorvastatin, which shows efficacy in attenuating chronic IH-induced myocardial and neural inflammation via suppressing TLR4/MyD88/NF-κB signaling pathways [33,40,94], also suppresses NLRP3 inflammasome activation [95], although this has not been tested in IH models. A recent clinical trial indicates promising protective effects of atorvastatin against cardiovascular risks in OSA patients [96].…”
Section: Mirna/nlrp3 Signalingmentioning
confidence: 99%
“…However, the oral administration of this lipophilic statin has disadvantages such as low bioavailability (less than 5%) and a short half-life (1-2 h) due to the degradation within the gastrointestinal tract and hepatic first-pass metabolism that limits its efficacy and potency [ 9 ] . Although there is ample evidence that lipophilic statins, such as SIM, are more efficient than hydrophilic statins in improving cardiac function and decreasing inflammation, minimizing their drawbacks is still needed [ 10 , 11 ] .…”
Section: Introductionmentioning
confidence: 99%